Precigen to host conference call on June 3 to discuss the pivotal Phase 2 study data of PRGN-2012 for the treatment of RRP presented at #ASCO24 and report first quarter 2024 financial results after the market close on May 14. https://bit.ly/3wtWPdb
Precigen
Biotechnology Research
Germantown, Maryland 4,583 followers
Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cell therapies.
About us
Precigen: Advancing Medicine with Precision™ Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.
- Website
-
http://www.precigen.com
External link for Precigen
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Germantown, Maryland
- Type
- Public Company
- Specialties
- Gene Therapy and Cell Therapy
Locations
-
Primary
Get directions
20358 Seneca Meadows Pkwy
Germantown, Maryland 20876, US
Employees at Precigen
Updates
-
#ASCO24 abstract titles are out! Precigen is excited to announce a late-breaking abstract for our pivotal Phase 2 study of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis has been selected for oral presentation. https://bit.ly/4brTFFV #Immunotherapy #Oncology #ClinicalTrial
-
-
Precigen is pleased to announce #ASCO24 titles and session information for two trials-in-progress abstracts for our PRGN-2009 AdenoVerse immunotherapy in oropharyngeal cancer and cervical cancer. https://bit.ly/3LqNK9i #Immunotherapy #Oncology #ClinicalTrials
Events & Presentations | Precigen
investors.precigen.com
-
The countdown begins! Only 2 months to go until the inaugural RRP Awareness Day, a multi-stakeholder event to raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials. View details at www.rrpawareness.org and join us!
Home
https://rrpawareness.org
-
Precigen is thrilled to team up with the RECURRENT RESPIRATORY PAPILLOMATOSIS FOUNDATION to launch the first international RRP Awareness Day, a multi-stakeholder event to raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials. View details: https://bit.ly/3TVz5rm #RecurrentRespiratoryPapillomatosis #RRPAwareness #RRPAwarenessDay #GivingVoicetoInspireChange
-
-
Precigen reports full year 2023 financial results and provides business updates. View press release: https://bit.ly/3vkUFfn
-
-
Join Precigen on Monday, March 25, 2024 at 1:00 PM ET for a virtual fireside chat hosted by Cantor Fitzgerald to discuss PRGN-2012 AdenoVerse immunotherapy for recurrent respiratory papillomatosis (RRP). View details: https://bit.ly/3LqNK9i #immunotherapy #vaccine
Events & Presentations | Precigen
investors.precigen.com
-
Join Precigen on Tuesday, March 19, 2024 at 4:30 PM ET for a conference call to discuss fourth quarter and full year 2023 financial results and general business updates. View details: https://bit.ly/3LqNK9i $PGEN
Events & Presentations | Precigen
investors.precigen.com
-
Worldwide, an estimated 300 million people are living with a rare disease. At #Precigen, we want to change that and are proud to be working on gene and cell therapies that target multiple rare diseases. #RareDiseaseDay2024
-
-
Join Precigen President and CEO, Helen Sabzevari, for a company presentation at the Oppenheimer & Co. Inc. 34th Annual Healthcare Life Sciences Conference. View details: https://bit.ly/3LqNK9i
Events & Presentations | Precigen
investors.precigen.com